ClinicalTrials.gg
RecruitingNCT07229911Updated Mar 5, 2026

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

A Phase 1 interventional study of TAK-781 and Placebo in Healthy Volunteers and Primary Sclerosing Cholangitis, sponsored by Takeda. Recruiting at 1 site in United States. Open to participants aged 18 Years to 68 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 68 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Planned enrollment
7th of 57
134 · median 27
Started
2026
with 3 others
Phase 1
19 of 75
5 open now
Primary completion
2028-04
later than 11 of 21 live
Registered
72nd of 75
by date

Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 7th largest by planned enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2026, is one of 19 in phase 1, reaches primary completion later than 11 of the 21 other live ones, and was the 72nd registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 68 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

The main aim of this study is to see if the drug TAK-781 is safe for healthy volunteers and for participants with PSC. The study will also look at how well participants can tolerate TAK-781. In addition, the study will check how the body absorbs, uses, and gets rid of TAK-781 (Pharmacokinetics [PK]), how the drug affects the body (Pharmacodynamics [PD]), and how the body's immune system reacts to TAK-781 (Immunogenicity).

The study consists of two phases (Phase 1a and 1b). Phase 1a includes two parts: Part 1 (Single Ascending Dose [SAD]) and Part 2 (Multiple Ascending Dose [MAD]). In Part 1, healthy participants will receive either single dose of TAK-781 or a placebo. A placebo looks the same as TAK-781 but has no medicine in it. In Part 2, healthy participants will receive multiple doses of TAK-781 or a placebo. In Phase 1b (Part 3), participants with large duct, non-cirrhotic PSC will receive a single dose of TAK-781.

Participants will be in the study for about 36 weeks.

03

Conditions studied

  • Healthy Volunteers
  • Primary Sclerosing Cholangitis

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Phase 1a (SAD and MAD)

  1. The participant is willing and able to fully comply with all trial procedures and requirements, in the investigator's opinion.
  2. The participant has provided (that is, in writing, documented via a signed and dated informed consent form (ICF) or electronic consent [e-consent] if applicable) and any required privacy authorization prior to the initiation of any trial procedures.
  3. Male at birth and female at birth participants aged 18 to 68 years, inclusive, at the time of consent.
  4. The participant is judged to be in good health (for example, no evidence of cardiovascular, liver, metabolic, gastroenterological, or kidney disease) by the investigator, based on clinical evaluations including laboratory safety tests, medical history, physical examination, , and vital sign measurements performed at the first screening visit.
  5. The participant must have a (BMI) of less than 30.0 kilograms per square meter (kg/m\^2) at the time of screening.
  6. Has not had frequent or heavy use (that is, near-daily) of medical or recreational cannabis for at least 3 months before screening.
  7. The participant must not be a person of (POCBP) defined by at least 1 of the following criteria:

    • Surgically sterile for at least 6 weeks at screening (defined as having undergone one of the following procedures: hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).
    • at screening (defined as no menses for 12 months without an alternative medical cause). A high follicle-stimulating hormone (FSH) level (greater than or equal to [>=]40 international units/liter [IU/L] in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
    • Has no uterus as a result of congenital condition. The participant must not donate ova for at least 6 months after the last dose of trial intervention.
  8. Male participants (based on sex at birth) must use highly effective contraception, from the date of signing the ICF, throughout the duration of the trial, and for 6 months after the last dose of trial intervention. The participant must not donate sperm for at least 6 months after the last dose of trial intervention.

Inclusion Criteria: Phase 1b (Non-Cirrhotic PSC)

  1. The participant is willing and able to fully comply with all trial procedures and requirements, in the investigator's opinion.
  2. The participant has provided informed consent (that is, in writing, documented via a signed and dated ICF or e-consent if applicable) and any required privacy authorization prior to the initiation of any trial procedures.
  3. Male at birth and female at birth participants aged 18 to 68 years, inclusive, at the time of consent.
  4. Confirmed diagnosis of large-duct PSC based on any 2 of the following 3 criteria:

    • Historical evidence of an elevated alkaline phosphatase (ALP) greater than [>] (ULN) from any laboratory.
    • Historical liver with histologic features consistent with large-duct PSC, in the appropriate clinical context (such as cholestatic liver enzyme profile, inflammatory bowel disease [IBD] history).
    • Historical abnormal cholangiography consistent with PSC as measured by magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography, or percutaneous transhepatic cholangiography.
  5. The participants must have a fibrogenesis biomarker over pre-defined level.
  6. The participants must have evidence for moderate/advanced fibrosis but not cirrhosis as defined by enhanced liver fibrosis (ELF) >=7.7 but less than or equal to(\<=)11.3 at Visit 1.
  7. No evidence of cholangiocarcinoma or any other on magnetic resonance imaging (MRI) at screening.
  8. Participants with a certain concomitant disease are allowed to enroll if pre-defined criteria are met.
  9. Participants must have certain additional laboratory parameters in specified ranges at screening.
  10. Has not had frequent or heavy use (that is, near-daily) of medical or recreational cannabis for at least 3 months before screening.
  11. A female and male participant (based on sex at birth) must use highly effective contraception, from the date of signing the ICF, throughout the duration of the trial, and for 6 months after the last dose of trial intervention. The participant must not donate ova or sperm for at least 6 months after the last dose of trial intervention.
  12. A POCBP must have a negative serum pregnancy test at first screening visit and urine pregnancy test on second screening visit and Day 1 before dosing.
  13. Participants must be able to be educated regarding the correct process/procedure, verbally state understanding and comply with the correct process/procedure of the administration SC IP for the duration of the trial.

Exclusion Criteria: Phase 1a (SAD and MAD)

  1. The participant is an employee of the sponsor or trial site, or an immediate family member (for example, spouse, parent, child, sibling) of an employee of the sponsor or trial site who is directly involved in the conduct of the trial.
  2. The participant has a known to any component of the formulation of TAK-781 or related compounds.
  3. The participant has a history of significant multiple and/or severe allergies (for example, food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
  4. The participant has a history or clinical evidence of bleeding diathesis or any coagulation disorder.
  5. The participant has a medical history of prior cholecystectomy.
  6. The participant has participated in another trial with other investigational agents or devices for any indication within 4 weeks or within 5 half-lives, for investigational drugs or biologics with a known half-life (whichever is longer), before the screening visit. The interval window from the previous trial will be derived from the date of the last trial medical procedure, and/or AE related to the trial IP or procedure in the previous trial to the screening visit of the current trial. Exceptions may be made for observational, natural history and nonintervention type studies with sponsor or designee approval.
  7. The participant has an and/or AST value greater than the ULN during screening.
  8. The participant has abnormal cholesterol: total cholesterol >240 milligrams per deciliter (mg/dL), low-density lipoprotein cholesterol (LDL-C) (>160 mg/dL), high-density lipoprotein cholesterol (HDL-C) (less than [\<]35 mg/dL), and triglycerides (>250 mg/dL) at screening. Lipid parameters may be repeated once under fasting conditions at the principal investigator's discretion. Eligibility will be determined based on the repeated results.
  9. The participant has rate \<=90milliliter per minutes per 1.73 square meters (mL/min/1.73m\^2) at screening.
  10. The participant screening ECG (triplicate) reveals a with Fridericia correction method (QTcF) >450 millisecond (ms) (male) or >460 ms (female).
  11. The participant has a history of torsades de pointes, ventricular arrhythmias (for example, ventricular tachycardia), heart block (excluding first-degree atrioventricular block), congenital long QT syndrome, or clinically significant ischemic ECG changes, including new ST-segment elevation or depression or new Q waves, as determined by the investigator. Benign ECG variants, such as early repolarization patterns, are not exclusionary if they occur without clinical symptoms or other evidence underlying cardiac disease.
  12. The participant has a confirmed supine systolic blood pressure >=140 millimetres of mercury (mmHg) and/or diastolic blood pressure >=90 mmHg at screening. If the participant's supine blood pressure exceeds these thresholds, the measurement should be repeated twice after the participant has remained in the supine position for at least 10 minutes. The average of the three supine blood pressure measurements will be used to determine eligibility.

    Resting BP is defined as a BP measurement obtained after the participant has been resting for a minimum of 5 minutes.

  13. The participant has a resting heart rate (HR) outside of the range of 55 to 100 beats per minute (bpm) (inclusive) at screening, confirmed on repeat testing within a maximum of 30 minutes. Athletic participants with HR \<55 bpm may be enrolled based on the investigator's judgement provided that the HR is >45 bpm.
  14. The participant has a positive urine screen for drugs of abuse at screening and Day -3.
  15. History of any malignancy diagnosed or treated within 5 years prior to screening.
  16. The participant consumes excessive amounts (defined as greater than 600 milligram (mg) of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
  17. Has a positive pregnancy test result during the screening period.
  18. Participants who test negative for surface antigen (HBsAg) but positive for hepatitis B core antibody (HBcAb) would be considered eligible if hepatitis B virus (HBV) deoxyribonucleic acid (DNA) results are negative at screening (as confirmed by HBV DNA polymerase chain reaction [PCR] reflex testing performed by the central laboratory). Participants with positive HBV DNA test results will not be eligible.
  19. Participants who test positive for virus (HCV) ribonucleic acid (RNA) at screening. Participants who are hepatitis C antibody (HCVAb) positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCV RNA at least 12 weeks before screening Visit1]).
  20. The participant tests positive for (HIV) at screening or currently receiving antiretroviral therapy.
  21. Has undergone major surgery or donated or lost 1 unit of blood (approximately 500 milliliters [mL]) within 4 weeks before the screening visit.
  22. Currently has or previously had a significant illness, as judged by the investigator, within 2 weeks of the first dose of trial intervention.
  23. The participant is unable to refrain from or anticipates using prohibited or excluded medications, herbal preparations, grapefruit juice, and other restricted substances or the required prior to administration of the first dose of trial intervention throughout the trial and until the follow-up visit.
  24. The participant is unable to refrain from or anticipate using smoking, vaping or nicotine-containing products 2 weeks before screening until the last follow-up visit.
  25. Clinically relevant drug or alcohol abuse within 12 months of screening.

    • A positive drug screen is exclusive unless it can be explained by a prescribed medication.
    • Participant with alcohol consumption greater than 4 units on any day or 14 units per week for male participants, or greater than 3 units on any day or 7 units per week for female participants [1 unit of alcohol is present in one 12 ounce (oz)/355 mL beer (approximately 5 percent (%) alcohol), one 5 oz/148 mL glass of wine (approximately 12% alcohol), and one 1.5 oz/44 mL measure of 80-proof liquor (approximately 40% alcohol)].

Exclusion Criteria: Phase 1b (Non-Cirrhotic PSC)

  1. Presence of documented secondary sclerosing cholangitis (such as ischemic cholangitis, recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis, surgical or blunt abdominal trauma, recurrent pyogenic cholangitis, cholelithiasis, choledocholithiasis, toxic sclerosing cholangitis due to chemical agents, or any other cause of secondary sclerosing cholangitis) on prior clinical investigations.
  2. Immunoglobulin G4-related Sclerosing Cholangitis based on historical diagnosis.
  3. Evidence of compensated cirrhosis. All participants will undergo a standardized cirrhosis exclusion assessment during screening including clinical, laboratory, and imaging evaluation (non-contrast MRI/ magnetic resonance elastography [MRE], MRCP+), documented using a predefined cirrhosis checklist completed and signed by both the site Principal Investigator (or Sub-Investigator) and the site radiologist. For participants with ELF >9.8 to \<=11.3 and/or liver stiffness measurement (LSM) >12.5 kilopascals (kPa), the checklist findings will undergo enhanced review by the sponsor medical monitor, who will provide final eligibility confirmation. A hepatic adjudication committee may be consulted in cases of ambiguity or disagreement. Participants will be excluded if >=2 of the following cirrhosis-associated features are present:

    • MRE liver stiffness >= 4.32 kPa.
    • Liver surface nodularity or lobar redistribution.
    • Spleen volume >400 mL/m\^2 body surface area or spleen length >13 centimeter (cm).
    • Segmental parenchymal signal heterogeneity, periportal edema, or lobar atrophy.
    • Collateral vessels or signs of portal hypertension (for example, varices, recanalized umbilical vein).
    • Radiologist overall impression consistent with cirrhosis.
    • Serum albumin \<3.5 grams per deciliter (g/dL).
  4. The participant has a medical history of prior cholecystectomy.
  5. Participants will be excluded if they meet any of the following criteria: a diagnosis of decompensated liver disease, or evidence of new signs of decompensation or clinically meaningful deterioration in liver function during the screening period, based on the judgment of the investigator. This may include, but is not limited to, significant changes in the following parameters: total , direct bilirubin, albumin, (INR), creatinine, alanine transaminase (ALT), or aspartate transaminase (AST).
  6. Presence or history of any of the following:

    • Ascites.
    • Hepatic encephalopathy.
    • Variceal bleeding.
    • score >6 (Class B or C), unless elevated INR is attributable to therapeutic anticoagulation. (Participants with compensated cirrhosis [for example, Child-Pugh A] will also be excluded if identified via the noninvasive cirrhosis exclusion algorithm, which includes assessment of ELF score, LSM, MRI/MRE, MRCP+, and clinical/laboratory parameters).
    • Model for End-Stage Liver Disease score >11.
  7. Concomitant overlap syndrome with hepatitis as diagnosed at screening by AST or ALT >5*ULN, and historical:

    • Positive smooth muscle antibody and/or liver-kidney microsomal antibody (LKM), or
    • Immunoglobulin G (IgG) >ULN, or
    • Biopsy suggestive for autoimmune hepatitis.
  8. Concomitant overlap syndrome with primary biliary cholangitis (PBC) as diagnosed by either historical:

    • Positive anti-mitochondrial autoantibodies, or
    • Biopsy suggestive for PBC.
  9. Clinically significant acute or chronic liver disease of an etiology other than PSC.
  10. Presence of a dominant stricture of clinical concern on MRCP at screening. However:

    - Participants with dominant stricture could be enrolled if the investigator determines that there is no evidence on MRI or cholangiography indicative of cholangiocarcinoma or that the stricture will likely not result in significant fluctuations in ALP during screening or trial period.

  11. Placement of a bile duct stent or percutaneous bile duct drain within 3 months of screening. However:

    - Participants who had undergone a stricture balloon dilation procedure can enroll in the trial after at least 4 weeks post procedure.

  12. History, evidence, or high suspicion of cholangiocarcinoma or other hepatobiliary malignancy based on imaging, laboratory values, and/or clinical symptoms.
  13. Ascending cholangitis within 60 days prior to screening and through Day 1. However:

    • Chronic preventive antibiotics for cholangitis are allowed in the trial.
    • Intermittent courses of antibiotics for the presumptive treatment of cholangitis are allowed if outside the 12-week window prior to screening.
  14. Prior liver transplantation.
  15. Screening ECG with clinically significant abnormalities as determined by the investigator.
  16. Participants who test negative for HBsAg but positive for HBcAb would be considered eligible if HBV DNA results are negative at screening (as confirmed by HBV DNA PCR reflex testing performed by the central laboratory). Participants with positive HBV DNA test results will not be eligible.
  17. Participants who test positive for HCV RNA at screening. Participants who are HCVAb positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCV RNA at least 12 weeks before baseline]).
  18. The participant tests positive for HIV at screening or currently receiving antiretroviral therapy.
  19. History of malignancy diagnosed or treated within 5 years prior to screening.
  20. The participant is unable to refrain from or anticipates using prohibited or excluded medications, herbal preparations, grapefruit juice, and other restricted substances or the required washout period prior to administration of the first dose of trial intervention throughout the trial and until the follow-up visit.
  21. The participant has not had frequent or heavy use (>=20 cigarettes per day) of smoking, vaping or nicotine-containing products or has not smoking-related complications.
  22. Clinically relevant drug or alcohol abuse within 12 months of screening.

    • A positive drug screen is exclusive unless it can be explained by a prescribed medication.
    • Participant with alcohol consumption greater than 4 units on any day or 14 units per week for male participants, or greater than 3 units on any day or 7 units per week for female participants [1 unit of alcohol is present in one 12 oz/355 mL beer (approximately 5% alcohol), one 5 oz/148 mL glass of wine (approximately 12% alcohol), and one 1.5 oz/44 mL measure of 80-proof liquor (approximately 40% alcohol)].
  23. Use of any prohibited concomitant medication is not allowed unless the participant has completed the washout period prior to Day 1.
  24. Participants should not be currently taking ursodeoxycholic acid, unless they have completed the washout period prior to Day 1.
  25. Severe allergic or anaphylactic reactions to any components of N-acetylgalactosamine small-interfering RNA therapeutics.
  26. Use of any investigational drug, biologic, or medical device, or participation in an interventional clinical trial, is prohibited within 4 weeks prior to screening or within 5 elimination half-lives for investigational drugs or biologics with a known half-life (whichever is longer). This restriction includes any pharmacologic, endoscopic, or other interventional procedures intended to modify or alter the course of PSC or its underlying disease processes.
  27. History of clinically significant unstable or untreated illness or any other major medical disorder that may have interfered with participant treatment, assessment, or compliance with the protocol.
  28. Any acute or chronic condition or other disease that, in the opinion of the investigator, would limit the ability of the participant to complete and/or participate in the clinical trial.
  29. Presence of any other conditions (for example, geographic or social), actual or projected, that the investigator determines would restrict or limit the participation of the participant for the duration of the trial.
  30. Individuals who are employed by the sponsor, a participating contract research organization (CRO), or the trial site - including permanent staff, temporary or contract workers, or designees directly involved in the conduct of the trial are excluded from participation. This exclusion also applies to immediate family members of employees of the sponsor, CRO, or trial site.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Phase 1a (Part 1): TAK-781 SAD

    Healthy participants will receive a single dose of TAK-781 injection at different dose level cohorts (1-6) on Day 1 of the pre-defined treatment period. An additional cohort may be added to repeat a selected dose from one of the previously tested dose levels in order to assess safety and tolerability and/or to verify the level of target engagement (TE).

    Drug: TAK-781

  • Placebo comparator
    Phase 1a (Part 1): Placebo SAD

    Healthy participants will receive TAK-781 matching placebo injection on Day 1 of the pre-defined treatment period.

    Drug: Placebo

  • Experimental
    Phase 1a (Part 2): TAK-781 MAD

    Healthy participants will receive multiple doses of TAK-781 injection across five cohorts (1 to 5), with or without a loading dose during the pre-defined treatment period. An additional cohort may be added to repeat a selected dose level and/or dosing regimen from one of the previously tested dose levels and/or dosing regimens in order to assess safety and tolerability, and/or to verify the level of TE.

    Drug: TAK-781

  • Placebo comparator
    Phase 1a (Part 2): Placebo MAD

    Healthy participants will receive multiple doses of TAK-781 matching placebo injection, with or without a loading dose during the pre-defined treatment period.

    Drug: Placebo

  • Experimental
    Phase 1b (Part 3): TAK-781

    Participants with non-cirrhotic PSC will receive a single dose of TAK-781 injection on Day 1 during the pre-defined treatment period. Part 3 will not begin until the SAD portion of the trial is considered complete.

    Drug: TAK-781

Interventions

  • DrugTAK-781

    TAK-781 injection.

  • DrugPlacebo

    TAK-781 matching placebo injection.

06

What researchers measure

Primary outcomes

  1. Phase 1a (SAD and MAD) and Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the trial intervention, whether or not the occurrence is considered related to the trial intervention. TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a trial intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the trial intervention.

    Time frame: Phase 1a (SAD) and 1b: From start of study drug administration up to End of Treatment (EOT)/Early termination (ET) (up to Week 20); Phase 1a (MAD): From start of study drug administration up to EOT/ET (up to Week 32)

  2. Phase 1a (SAD and MAD) and Phase 1b: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values

    Laboratory parameters will include hematology, chemistry and urinalysis. Any clinically significant change in laboratory values will be determined at the investigator's discretion.

    Time frame: Phase 1a (SAD) and 1b: From start of study drug administration up to EOT/ET (up to Week 20); Phase 1a (MAD): From start of study drug administration up to EOT/ET (up to Week 32)

  3. Phase 1a (SAD and MAD) and Phase 1b: Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Parameters

    The 12-lead ECG will be evaluated. Any clinically significant change in ECG assessment will be determined at the investigator's discretion.

    Time frame: Phase 1a (SAD) and 1b: From start of study drug administration up to EOT/ET (up to Week 20); Phase 1a (MAD): From start of study drug administration up to EOT/ET (up to Week 32)

  4. Phase 1a (SAD and MAD) and Phase 1b: Number of Participants With Clinically Significant Changes in Vital Sign Values

    Vital signs will include measurement of oral body temperature, supine blood pressure and heart rate. Any clinically significant change in vital signs will be determined at the investigator's discretion.

    Time frame: Phase 1a (SAD) and 1b: From start of study drug administration up to EOT/ET (up to Week 20); Phase 1a (MAD): From start of study drug administration up to EOT/ET (up to Week 32)

Secondary outcomes

  1. Phase 1a and 1b: Maximum Observed Plasma Concentration (Cmax) of TAK-781

    Cmax of TAK-781 will be reported.

    Time frame: Predose up to 2 days post-dose

  2. Phase 1a and 1b: Time of First Occurrence of Plasma Cmax (Tmax) of TAK-781

    Tmax of TAK-781 will be reported.

    Time frame: Predose up to 2 days post-dose

  3. Phase 1a and 1b: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of TAK-781

    AUCinf of TAK-781 will be reported.

    Time frame: Predose up to 2 days post-dose

  4. Phase 1a and 1b: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) of TAK-781

    AUClast of TAK-781 will be reported.

    Time frame: Predose up to 2 days post-dose

  5. Phase 1a: Percentage Change From Baseline in TE Biomarker Area Under the Effect Curve 0 to 9 Hours (AUEC0-9h)

    Percentage change from baseline in TE biomarker AUEC0-9h will be reported.

    Time frame: Phase 1a: 0 to 9 hours post-dose

  6. Phase 1b: Percentage Change From Baseline in Fibrogenesis Biomarker Levels

    Percentage change from baseline in fibrogenesis biomarker levels will be reported.

    Time frame: Baseline up to Week 12

  7. Phase 1b: Percentage Change From Baseline in TE Biomarker Through Week 12

    Percentage change from baseline in TE biomarker through Week 12 will be reported.

    Time frame: Baseline up to Week 12

  8. Phase 1a (SAD and MAD) and 1b: Number of Participants With Anti-drug Antibodies (ADAs) to TAK-781

    Number of participants with ADAs to TAK-781 will be reported.

    Time frame: Phase 1a (SAD) and 1b: Baseline up to Week 20; Phase 1a (MAD): Baseline up to Week 32

07

Study locations

1 of 1 sites recruiting
  • ICON
    Salt Lake City, Utah 84124, United States
    Recruiting
    • Site Contact · Contact801-269-8200
    • Matthew D. Johnston, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Apr 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 17, 2025
StartActual
Jan 7, 2026
Primary completionEst.
Apr 6, 2028
CompletionEst.
Apr 6, 2028
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07229911
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Jan 7, 2026
Primary completion
Apr 6, 2028 (estimated)
Completion
Apr 6, 2028 (estimated)
Last update
Mar 5, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion